AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
- Conditions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT06457854
- Locations
- 🇧🇷
Clínica AMO, Salvador, Bahia, Brazil
🇧🇷Liga Norte Rio Grandense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
🇧🇷Clínica Viver, Santa Maria, Rio Grande Do Sul, Brazil
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06455449
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
- Conditions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06455462
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT06450197
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Real-World Treatment Study of Soliris (Eculizumab)
- Conditions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT06448715
- Locations
- 🇰🇷
National Cancer Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Volrustomig Priming Regimens Exploratory Phase II Platform Study
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06448754
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT06435273
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06432764
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06429761
Fasenra Pediatric Japan Post-Marketing Study(PMS)
- Conditions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06427876
- Locations
- 🇯🇵
Research Site, Saitama, Japan